Skip navigation
sponsored by 

FDA approves patch to treat depression

Drug label will carry warning about dietary restrictions

updated 1:38 p.m. ET Feb. 28, 2006

WASHINGTON - Federal regulators approved the first antidepressant skin patch on Tuesday, providing a different way to administer a drug already used by Parkinson’s disease patients.

The Food and Drug Administration approved the selegiline transdermal patch, agency spokeswoman Susan Cruzan said. The drug belongs to a class of medicines that is rarely a first or even second choice to treat depression.

It will be marketed as Emsam, said Somerset Pharmaceuticals Inc., which developed the drug, and Bristol-Myers Squib Co., which will market it.

Story continues below ↓
advertisement

The FDA will require the drug to bear a so-called “black-box” warning of the risks of suicidal thoughts and behaviors in children and adolescents treated with antidepressants. The drug is meant for use only by adults.

The drug’s label also will carry a long list of foods, drinks and other drugs that patients must avoid while using the Emsam patch. The warnings are typical of the class of drugs to which it belongs.

Selegiline, approved by the FDA in 1989 to help treat Parkinson’s disease, is a monoamine oxidase inhibitor, or MAOI. Typically, doctors prescribe MAOIs only if patients don’t respond to other antidepressants, including selective serotonin reuptake inhibitors like Prozac, Zoloft and Paxil.

Although health officials say MAOIs are safe when used correctly, the drugs can cause dangerous interactions, including sudden and severe rises in blood pressure that can lead to a stroke, when patients consume food or drinks that contain a substance called tyramine — found in draft beer, red wine, fava beans, salamis, aged cheeses, soy sauce and other products.

© 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Resource guide

Get Your 2008 Credit Score

Find a business to start

Try for Free

Search Jobs

Find Your Dream Home

$7 trades, no fee IRAs

Find your next car